Latest News
News Archive
- First patient dosed in Phase 3 liver cancer trial of JS207 and JS007
- China accepts application for subcutaneous toripalimab in urothelial carcinoma
- Final NEOTORCH analysis presented at the ESMO Congress 2026
- Phase 3 lymphoma trial of JS203 and chemotherapy doses first patient
- Junshi and Fosun Wanbang sign a Greater China agreement for roconkibart
- Junshi reports primary endpoint results in the NEOTORCH study
- China approves intravenous toripalimab combination for urothelial carcinoma
- China accepts subcutaneous toripalimab applications covering 12 indications
- China approves two additional indications for ongericimab
- Junshi reports U.S. approval of LOQTORZI for nasopharyngeal carcinoma
Media Contact
For press enquiries, contact Zhi Li at Junshi Biosciences.